Unknown

Dataset Information

0

De Novo EGFR ‐ALK and EGFR ‐ROS1 Co‐Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis

ABSTRACT:

SUBMITTER: Shen L 

PROVIDER: S-EPMC12304520 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.
| S-EPMC10807714 | biostudies-literature
Unknown Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC.
| S-EPMC6831109 | biostudies-literature
Unknown Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.
| S-EPMC5943229 | biostudies-literature
Unknown Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
| S-EPMC5403565 | biostudies-literature
Unknown Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations.
| S-EPMC9808475 | biostudies-literature
Unknown Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations.
| S-EPMC5123695 | biostudies-literature
Unknown Targeting EGFR and ALK in NSCLC: current evidence and future perspective.
| S-EPMC6310340 | biostudies-literature
Unknown Characteristics of Short-Term Survivors With <i>ALK</i> or <i>ROS1</i>-Altered Metastatic NSCLC.
| S-EPMC12605057 | biostudies-literature
Unknown PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
| S-EPMC4371934 | biostudies-literature
Unknown TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC.
| S-EPMC6980625 | biostudies-literature